|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Arda Güler
Contributors
Dr. Cemal Ozanalp
Dr. Emre Aydın
Dr. Kübra Okumuş
Dr. Merve Ortakaya
Dr. Muhammed Mustafa Yıldız
Dr. Süleyman Atalay
Dr. Şevval Kılıç
Dr. Veli Sonnur Şenlik
|
| |
|
|
|
Updated Recommendations in the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart DiseaseTürk Kardiyoloji Derneði Genç Kardiyologlar Bülteni - Updated Recommendations in the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease (Dr. Merve Ortakaya)Updated Recommendations in the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
Written by Dr. Merve Ortakaya
Reference: Praz F, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025. doi: 10.1093/eurheartj/ehaf194.
Introduction
Current guidelines for the management of valvular heart disease serve as an essential guide for clinicians. The ESC 2025 Guidelines on Valvular Heart Disease make clinical decision-making more systematic and practical with their updated recommendations. This bulletin provides a summary of the revised recommendations from the guideline.
Commentary:
The revised recommendations in the 2025 ESC Guidelines on Valvular Heart Disease emphasize patient-centered, individualized, and long-term management strategies. The Heart Team approach is now recommended not only for complex cases but also for the comprehensive evaluation of all valvular diseases.
For TAVI candidates with concomitant coronary artery disease, non-invasive imaging—such as coronary CT angiography—is preferred over invasive methods in low-to-intermediate risk groups. In native valve disease, rhythm control in atrial fibrillation has regained importance; during mitral valve surgery, concomitant surgical ablation and left atrial appendage closure are now more strongly recommended.
Another key update concerns DOAC use in rheumatic mitral stenosis, where the contraindication threshold has been redefined: DOACs are contraindicated in patients with a mitral valve area ≤2 cm², while individualized decisions are advised for those with larger valve areas.
In mitral and tricuspid regurgitation, early diagnosis and timely intervention are emphasized, with a stronger recommendation for transcatheter mitral interventions (especially TEER) in patients with suitable anatomy and moderate-to-high surgical risk.
Overall, the guideline promotes a holistic, multidisciplinary approach aimed at improving long-term outcomes through structured, collaborative clinical decision-making.
|
